

Table S3. PCR Primers

Gene	Primer pairs (5'-3'; Forward and Reverse)	Tm (°C)	Product (bp)	Reference
ABCG-2	GGGTTCTCTTCTTCCTGACGACC TGGTTGTGAGATTGACCAACAGACC	65	398	CW Scharenberg et al. Blood 2002;99: 507
Alb	TGCTTGAATGTGCTGATGACAGGG AAGGCAAGTCAGCAGGCATCTCATC	60	160	R Schwartz et al. J Clin Invest 2002; 109: 1291
AFP	TGCAGCCAAAGTGAAGAGGGAAGA CATAGCGAGCAGCCCAAAGAAGAA	60	160	R Schwartz et al. J Clin Invest 2002; 109: 1291
β-Actin	AGAGCTATGAGCTGCCTGAC CTGATCCACATCTGCTGGAA	65	361	Y. Heremans et al. J Cell Biol 2002;159: 303
β2-microglobulin	AGCAAGGACTGGTCTTT CTCGATCCCACTTAACTATCT	54	124	Current authors (MI)
CK-19	ATGGCCGAGCAGAACCGGAA CCATGAGCCGCTGGTACTCC	60	308	R Schwartz et al. J Clin Invest 2002; 109: 1291
E-Cadherin	TTGGTCTACGCTGGG AGTTGGGAAATGTGAGCA	60	139	Current authors (MI)
EGF receptor	ATTCCGAGACGAAGCC CACGAGCCGTGATCTG	60	162	Current authors (MI)
Frizzled-1	GAACCTTCCTCCAAC TTCATGGC CATTCCATTTTACAGACCGG	60	398	YW Qiang et al. Oncogene 2003;22:1536
Frizzled -2	GGTGAGCCAGCACTGCAAGAG CCTAAAAGTGAAATGGTTTCGATCG	60	310	YW Qiang et al. Oncogene 2003;22:1536
Frizzled -3	GCTGTACTCACAGTTAACATG GCTAAAATACCCTTGCTGATTT	45	450	YW Qiang et al. Oncogene 2003;22:1536
Frizzled -4	TGCCTTTTCAGGGCAAAGTG ACAGGAAGAGATTTATGGAATG	55	378	YW Qiang et al. Oncogene 2003;22:1536
Frizzled -5	TACCCAGCCTGTCGCTAAAC AAAACCGTCCAAAGATAAACTGC	55	247	YW Qiang et al. Oncogene 2003;22:1536
Frizzled -6	ACATCTCTGCTTGTTTAC GATCTGTGAAATTCCTAA	45	732	YW Qiang et al. Oncogene 2003;22:1536
Frizzled -7	GTTTGGATGAAAAGATTTTCAGGC GACCACTGCTTGACAAGCACAC	60	294	YW Qiang et al. Oncogene 2003;22:1536
Frizzled -8	ACAGTGTGATTGCTATTAGCATG GTGAAATCTGTGTATCTGACTGC	55	268	YW Qiang et al. Oncogene 2003;22:1536
Frizzled -9	CCCTAGAGACAGCTGACTAGCAG CGGGGGTTTATTCCAGTCACAGC	60	270	YW Qiang et al. Oncogene 2003;22:1536

Frizzled -10	ACACGTCCAACGCCAGCATG ACGAGTCATGTTGTAGCCGATG	60	160	YW Qiang et al. Oncogene 2003;22:1536
HNF-1α	GTGTCTACAACGGTTTGCC TGTAGACACTGCTACTAAGG	52	251	I Lemm I. et al. Mol Carcinogenesis 1999; 24:305
HNF-1β	GAAACAATGAGATCACTTCCTCC CTTTGTGCAATTGCCATGACTCC	56	374	I Lemm et al. Mol Carcinogenesis 1999; 24:305
HNF-3α	CAACATGTTTCGAGAACGGCT CCACTGTGGTCCAGAGTCTG	56	263	RK Giri (unpublished)
HNF-3β	CACCCTACGCCTTAACCAC GGTAGTAGGAGGTATCTGCGG	52	235	Current authors (MI)
HNF-4	CTGCTCGGAGCCACAAAGAGATCCATG ATCATCTGCCACGTGATGCTCTGCA	58	370	L Suaud et al. Biochem Biophys Res Commun 1997;235: 820
HGF	ACCACACGAACACAGC AGACTTCGTAGCGTACC	60	134	Current authors (MI)
c-Met	ACAACCCGAATACTGCC AGGATACGGAGCGACA	54	190	Current authors (MI)
Nanog	AGAACTCTCCAACATCCTG GGGTAGGTAGGTGCTG	54	147	Current authors (MI)
Notch-1	GCGGCCGCCTTTGTGGTTCTGTTC GCCGGCGCGTCTCCTCTTCC	65	500	J. Walsh et al. APMIS, 2003; 111: 197-210
Notch-2	TCGTGCAAGAGCCAGTTACCC AATGTCATGGCCGCTTCAGAG	65	530	J. Walsh et al. APMIS, 2003; 111: 197-210
Oct-4	AGTGAGAGGCAACCTG CGTTGTGCAAGTCGC	53	165	Current authors (MI)
α-SMA	AGTACCCGATAGAACATGG TTTTCTCCCGTTGGC	60	153	Current authors (MI)
TGF-β1	TGATGTCACCGGAGTTG GAACCCGTTGATGTCCA	58	124	Current authors (MI)
TGF-β2	CAACAGACCAACCGGC GTACCCTTTGGGTTTCGT	58	144	Current authors (MI)
TGF-β1 Receptor	CGTGCTGACATCTATGCAAT AGCTGCTCCATTGGCATAAC	54	251	U Wulbrand et al. Eur J Clin Invest 1998; 28:1038
TGF-β2 Receptor	TGCGTCTGGACCCTAC ACTGCATTACAGCGAGAT	58	187	RK Giri (unpublished)
Vimentin	CACCTACAGCCTCTACG AGCGGTCATTACAGCTC	60	170	Current authors (MI)